[go: up one dir, main page]

CN111000897A - aerosol - Google Patents

aerosol Download PDF

Info

Publication number
CN111000897A
CN111000897A CN201911194896.0A CN201911194896A CN111000897A CN 111000897 A CN111000897 A CN 111000897A CN 201911194896 A CN201911194896 A CN 201911194896A CN 111000897 A CN111000897 A CN 111000897A
Authority
CN
China
Prior art keywords
industrial hemp
essential oil
extraction
aerosol
leaves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911194896.0A
Other languages
Chinese (zh)
Inventor
项伟
顾文云
李铖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Hanmusen Biotechnology Co ltd
Original Assignee
Yunnan Hanmusen Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Hanmusen Biotechnology Co ltd filed Critical Yunnan Hanmusen Biotechnology Co ltd
Priority to CN201911194896.0A priority Critical patent/CN111000897A/en
Publication of CN111000897A publication Critical patent/CN111000897A/en
Priority to PCT/CN2020/137850 priority patent/WO2021232777A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)

Abstract

本发明公开了一种气雾剂，包括工业大麻花叶香精油和药用成分，本发明中添加的工业大麻花叶香精油仅含有小分子的赋香成分，不含二帖类化合物，如大麻二酚、四氢大麻酚等药用活性成分，因此对被添加的对象的生物活性不会有明显影响。但是，添加了工业大麻花叶香精油后，可以让所有的“无味大麻酚类产品”具有天然工业大麻的标志性香气，补齐感官缺失、心理安慰和暗示作用，能够大幅提高原来产品的市场价值和消费者的认知度。本发明的“在无味大麻酚类气雾剂中添加工业大麻花叶香精油”，可以提高使用天然医用大麻的病患对无味产品的接受度。The invention discloses an aerosol, which includes industrial hemp mosaic essential oil and medicinal components. The industrial hemp mosaic essential oil added in the present invention only contains small-molecule fragrance components, and does not contain two types of compounds, such as Medicinal active ingredients such as cannabidiol and tetrahydrocannabinol will not significantly affect the biological activity of the added object. However, after adding industrial hemp flower and leaf essential oil, all "odorless cannabidiol products" can have the signature aroma of natural industrial hemp, which can make up for sensory deficits, psychological comfort and suggestive effects, and can greatly increase the market of the original products. value and consumer perception. The "adding industrial hemp mosaic essential oil to the odorless cannabinoid aerosol" of the present invention can improve the acceptance of the odorless product by the patients who use natural medical cannabis.

Description

Aerosol formulation
Technical Field
The invention relates to the field of medicines, in particular to an aerosol.
Background
The use of cannabis as a drug and medicine dates back to 440 B.C., but the psychoactive drug, Tetrahydrocannabinol (THC), was used in the past. The side effects of tetrahydrocannabinol, such as hallucinography and psychosis, limit its medical application. In the last decade, along with the research and discovery of a brand new pharmacological action mechanism of Cannabidiol (CBD) without a mental action component in cannabis sativa, the research and application of cannabinol compounds are restarted under the guidance of Europe and America all over the world, and particularly the research on Cannabidiol extracted from low-THC and low-toxicity industrial cannabis sativa and the like. Modern pharmaceutical research proves that cannabidiol has opposite effects with tetrahydrocannabinol, can treat pain, epilepsy, spasm, psychosis and depression, has slight side effect, can be used for a long time, and has good tolerance and no addiction. Cannabidiol based drugs, such as epididolex and Sativex, have been approved for marketing in the united states and europe, respectively.
In recent years, patients who have used cannabis for medical purposes in the past because of spasticity, depression and pain have gradually begun to switch to the use of the psychoactive, safer cannabidiol products. However, in western countries, there are limitations to production costs, process technology and western habits. Many cannabidiol products, including the functional ingredients of Epidiolex and Sativex described above, are highly purified, even chemically synthesized, with only 1, or 2 chemical components in the product. Wherein the characteristic aroma of the hemp has been completely removed. Thus, the former patients who use natural cannabis for medical purposes have a reduced acceptance of odorless products, and odorless cannabidiol products require patient re-adaptation, and most importantly, lack of psychological comfort and cueing of the drugs that are very useful during treatment.
Disclosure of Invention
The invention aims to provide an aerosol which is added with micromolecular perfuming ingredients and solves the problem that the acceptance of odorless products of patients who originally use natural medical cannabis is reduced due to odorless cannabidiol products.
In order to solve the technical problems, the invention adopts the following technical scheme:
an aerosol comprises essential oil of industrial hemp flower and leaf and medicinal components.
Preferably, the industrial hemp flower and leaf essential oil is obtained by primary extraction and fine extraction of industrial hemp flower and leaf, wherein,
carrying out initial extraction: performing supercritical extraction on industrial hemp to obtain a primary extract;
fine extraction: and carrying out chromatography treatment on the primary extract to obtain the industrial cannabis sativa leaf essential oil.
Preferably, the initial extraction step is carried out in an extraction kettle, the flow of the supercritical carbon dioxide fluid is one extraction kettle volume every 3-10 minutes, for example, the volume of the extraction kettle is 25 liters, the flow rate of the carbon dioxide is 25 liters every 3-10 minutes, the temperature in the extraction kettle is 25-60 ℃, the pressure in the extraction kettle is 10-40MPa, and the extraction time is 20-360 min.
Preferably, an entrainer is added in the supercritical extraction step, the entrainer is at least one of ethanol, n-hexane, cyclohexane or ethyl acetate, and the mass ratio of the use amount of the entrainer to the materials is 0.1-10: 100.
Preferably, the industrial hemp flower and leaf essential oil is a first distillation section obtained by rectifying industrial hemp flower and leaf by a rectification method, the rectification method comprises the steps of extracting a primary extract from powder obtained by grinding industrial hemp flower and leaf by using an organic solvent, and rectifying the extract at the temperature of 110-190 ℃, wherein the organic solvent comprises gasoline, n-hexane, cyclohexane, alcohol, chloroform or ethyl acetate.
Preferably, the industrial hemp flower and leaf and water are boiled together, the distillation product is subjected to co-distillation, and the upper-layer component obtained after the distillation product is condensed and layered is the industrial hemp flower and leaf essential oil, wherein the weight ratio of the industrial hemp flower and leaf to the water is 1: 1-2.
Preferably, the industrial hemp flower and leaf is obtained by drying flower and leaf of industrial hemp at 90-120 deg.C until the water content is less than 10%, and pulverizing to 50-200 mesh.
Preferably, the aerosol also comprises a penetrating agent and a propellant, wherein the industrial cannabis sativa leaf essential oil accounts for less than 3% of the total mass of the aerosol.
Preferably, the osmotic agent is at least one of azone, menthol and chondroitin sulfate; the propellant is compressed gas of nitrogen, carbon dioxide or nitrous oxide, hydrocarbons, fluorochloroalkanes or hydrofluorocarbons.
Preferably, the penetrating agent, the industrial hemp flower and leaf essential oil, the medicinal components and the solvent are mixed to prepare a solution; filling the obtained solution into an aerosol can, sealing, and filling propellant.
The invention uses methods such as steam distillation, rectification or supercritical extraction separation and the like to prepare the 'essential oil of industrial hemp flower leaves' from the industrial hemp flowers, and the essential oil only contains micromolecular aromatizing components, which is the key or core step of the application.
Compared with the prior art, the invention has the beneficial effects that:
the industrial hemp flower and leaf essential oil added in the invention only contains micromolecular aromatizing components and does not contain diterpene compounds, such as cannabidiol, tetrahydrocannabinol and other medicinal active components, so that the biological activity of the added object is not obviously influenced. However, after the industrial hemp flower and leaf essential oil is added, all odorless hemp phenolic products can have the characteristic aroma of natural industrial hemp, and the odorless hemp phenolic products complement sensory loss, psychological comfort and suggestion effects. The market value of the original product and the cognition degree of the consumer can be greatly improved. The addition of the industrial hemp flower and leaf essential oil in the odorless hemp phenol aerosol can improve the acceptance of patients using natural medical hemp on odorless products.
The industrial hemp flower and leaf essential oil in the application mainly comprises sesquiterpenes and monoterpenes, mainly comprises caryophyllene (caryophylelene), trans α -bergamotene (trans- α -bergamotene), humulene (humulene), cis β -farnesene (cis- β -farnesene) and α -pinene (α -pinene), d-limonene (d-limonene), p-cymol (p-cymol 0.65%) and cineol (cineole) and the like, and the extraction rate of the industrial hemp flower and leaf essential oil can reach 0.1% of the total weight of the industrial hemp flower and leaf essential oil, wherein the identified aromatizing components account for 80% of the industrial hemp flower and leaf essential oil and are far superior to the prior art.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Comparative example:
an aerosol comprises aromatic cannabinol product as medicinal component, penetrant and propellant, wherein the penetrant is at least one of azone, menthol and chondroitin sulfate; the propellant is at least one of compressed gas of nitrogen, carbon dioxide or nitrous oxide, hydrocarbons, chlorofluorocarbons, hydrochlorofluorocarbons or hydrofluorocarbon compounds; mixing penetrant, industrial hemp flower and leaf essential oil, medicinal components and solvent to prepare solution; filling the obtained solution into an aerosol can, sealing, and filling propellant. Parts not mentioned or not described in detail in this comparative example, such as how to prepare the solution, how to seal, how to fill the propellant, whether or not a solvent is required, the kind of solvent, etc., are within the prior art.
Example 1:
on the basis of the comparative example 1, the industrial hemp flower and leaf essential oil is added, and the industrial hemp flower and leaf essential oil is obtained by carrying out primary extraction and fine extraction on industrial hemp leaves, wherein,
carrying out initial extraction: carrying out supercritical extraction on industrial hemp, wherein an entrainer is added in the supercritical extraction step, the entrainer can be at least one of ethanol, n-hexane, cyclohexane or ethyl acetate, and the mass ratio of the use amount of the entrainer to the materials is 0.1-10: 100; the primary extraction step is carried out in an extraction kettle, the flow of supercritical carbon dioxide fluid is one extraction kettle volume every 3-10 minutes, the temperature in the extraction kettle is 25-60 ℃, the pressure in the extraction kettle is 10-40MPa, and the extraction time is 20-360min, so as to obtain a primary extract;
fine extraction: and carrying out chromatography treatment on the primary extract to obtain the industrial cannabis sativa leaf essential oil.
Wherein the volume ratio of the entrainer to the cyclohexane is 2:1, the ratio of the entrainer flow rate to the supercritical carbon dioxide fluid flow rate is 0.02, the supercritical carbon dioxide fluid flow rate is 6 minutes and one extraction kettle volume, the temperature in the extraction kettle is 40 ℃, the pressure in the extraction kettle is 25MPa, and the extraction time is 220 minutes, the effect is optimal, the extraction rate of the industrial hemp flower and leaf essential oil can reach 0.103 percent of the total weight of the industrial hemp flower and leaf, and the identified fragrance-providing component accounts for 82.1 percent of the industrial hemp flower and leaf essential oil.
Example 2:
on the basis of the comparative example 1, the industrial hemp flower and leaf essential oil is added, the industrial hemp flower and leaf essential oil is a first distillation section obtained by rectifying the industrial hemp flower and leaf by using a rectification method, the rectification method specifically comprises the steps of extracting a primary extract from powder obtained by grinding hemp flower and leaf by using an organic solvent, and rectifying the extract at the temperature of 110-190 ℃, wherein the organic solvent comprises gasoline, normal hexane, cyclohexane, alcohol, chloroform or ethyl acetate.
Wherein the organic solvent is cyclohexane, the effect is optimal when the rectification temperature is 155 ℃, the extraction rate of the essential oil of the leaves of the industrial hemp flowers and leaves can reach 0.93 percent of the total weight of the leaves of the industrial hemp flowers and leaves, and the identified proportion of the aromatizing components in the essential oil of the leaves of the industrial hemp can reach 78.7 percent.
Example 3:
adding essential oil of flowers and leaves of industrial hemp on the basis of the comparative example 1, drying the flowers and leaves of the industrial hemp at 90-120 ℃ until the water content is less than 10%, then crushing the flowers and leaves of the industrial hemp to 50-200 meshes, boiling the crushed flowers and leaves together with water according to the weight ratio of 1:1-2, co-distilling the crushed flowers and leaves, and condensing and layering the distillate to obtain an upper-layer component, namely the essential oil of the flowers and leaves of the industrial hemp, wherein the weight ratio of the flowers and leaves of the industrial hemp to the water is 1: 1-2.
Wherein, flowers and leaves of industrial hemp are dried at 105 ℃ until the water content is less than 8 percent, then are crushed into 70-80 meshes, and are boiled together with water according to the weight ratio of 1:1.5, and the effect is optimal. The extraction rate of the essential oil of the industrial hemp flowers and leaves can reach 0.91 percent of the total weight of the industrial hemp flowers and leaves, wherein the identified perfuming ingredients account for 77.8 percent of the essential oil of the industrial hemp flowers and leaves.
The components of the industrial hemp flower and leaf essential oil obtained with the best results in examples 1-3 were tested and the results are shown in the following table, wherein the control group was a non-odorous cannabinol product.
Figure RE-RE-GDA0002402466360000041
The results of counting the usage effects of the aerosols obtained in examples 1 to 3 and the control group are shown in the following table.
Figure RE-RE-GDA0002402466360000042
As can be seen from the above table, the therapeutic effects of examples 1 to 3 on pain, epilepsy, convulsions, psychosis and depression were all significantly improved as compared with the control group.
Although the invention has been described herein with reference to a number of illustrative embodiments thereof, it should be understood that numerous other modifications and embodiments can be devised by those skilled in the art that will fall within the spirit and scope of the principles of this disclosure. More specifically, various variations and modifications are possible in the component parts and/or arrangements of the subject combination arrangement within the scope of the disclosure and claims of this application. In addition to variations and modifications in the component parts and/or arrangements, other uses will also be apparent to those skilled in the art.

Claims (10)

1.一种气雾剂，其特征在于：包括工业大麻花叶香精油和药用成分。1. an aerosol is characterized in that: comprise industrial hemp mosaic essential oil and medicinal ingredient. 2.根据权利要求1所述的气雾剂，其特征在于，由工业大麻花叶经初提和精提得到工业大麻花叶香精油，其中，2. aerosol according to claim 1, is characterized in that, obtains essential oil of industrial hemp mosaic leaves through initial extraction and refined extraction from industrial hemp mosaic leaves, wherein, 初提：对工业大麻进行超临界萃取，得到初提物；Preliminary extraction: supercritical extraction of industrial hemp to obtain primary extract; 精提：对初提物进行层析处理，得到工业大麻花叶香精油。Refined extraction: The primary extract is subjected to chromatographic treatment to obtain the essential oil of industrial hemp mosaic leaves. 3.根据权利要求2所述的气雾剂，其特征在于，所述初提步骤在萃取釜中进行，超临界二氧化碳流体流量为每3-10分钟一个萃取釜容积，萃取釜内温度为25-60℃，萃取釜内压力为10-40MPa，萃取时间20-360min。3. aerosol according to claim 2, is characterized in that, described preliminary step is carried out in extraction kettle, and supercritical carbon dioxide fluid flow is an extraction kettle volume every 3-10 minutes, and temperature in extraction kettle is 25 ℃. -60℃, the pressure in the extraction kettle is 10-40MPa, and the extraction time is 20-360min. 4.根据权利要求2所述的气雾剂，其特征在于，所述超临界萃取步骤中加入有夹带剂，所述夹带剂为乙醇、正己烷、环己烷或乙酸乙酯中的至少一种，所述夹带剂的用量与物料的质量比为0.1-10:100。4. aerosol according to claim 2, is characterized in that, in described supercritical extraction step, is added with entrainer, and described entrainer is at least one in ethanol, normal hexane, cyclohexane or ethyl acetate The mass ratio of the amount of the entraining agent to the material is 0.1-10:100. 5.根据权利要求1所述的气雾剂，其特征在于，所述工业大麻花叶香精油是利用精馏法对工业大麻花叶进行精馏得到的第一馏分段，所述精馏的具体方法是将工业大麻花叶研磨后的粉末用有机溶剂提取出初浸膏，将所述浸膏置于110-190℃条件下精馏，所述有机溶剂包括汽油、正己烷、环己烷、酒精、氯仿或乙酸乙酯。5. aerosol according to claim 1, is characterized in that, described industrial hemp mosaic essential oil is the first distillation segment that utilizes rectification method to carry out rectification to industrial hemp mosaic, and described rectifying The specific method is to extract the primary extract from the ground powder of industrial hemp mosaic leaves with an organic solvent, and place the extract under the condition of 110-190 ℃ for rectification. The organic solvent includes gasoline, n-hexane, cyclohexane, Alcohol, chloroform or ethyl acetate. 6.根据权利要求1所述的气雾剂，其特征在于，将工业大麻花叶与水一同煮沸，共蒸馏，将馏出物冷凝分层后得到的上层组分即为工业大麻花叶香精油，其中工业大麻花叶与水的重量比为1:1-2。6. aerosol according to claim 1, is characterized in that, industrial hemp mosaic and water are boiled together, co-distillation, and the upper layer component obtained after distillate condensation layering is industrial hemp mosaic Essential oil, wherein the weight ratio of industrial hemp leaves and water is 1:1-2. 7.根据权利要求2-6任意一项所述的气雾剂，其特征在于，所述工业大麻花叶是将工业大麻的花和叶子在90-120℃下干燥至含水率小于10％，然后粉碎至50-200目得到。7. The aerosol according to any one of claims 2-6, characterized in that, the industrial hemp mosaic leaves are dried to a moisture content of less than 10% by drying the flowers and leaves of industrial hemp at 90-120°C, Then crushed to 50-200 mesh to get. 8.根据权利要求1所述的气雾剂，其特征在于，还包括渗透剂、抛射剂，所述工业大麻花叶香精油占气雾剂总质量的3％以下。8 . The aerosol according to claim 1 , further comprising a penetrant and a propellant, and the essential oil of industrial hemp mosaic leaves accounts for less than 3% of the total mass of the aerosol. 9 . 9.根据权利要求1所述的气雾剂，其特征在于，所述渗透剂为氮酮、薄荷醇和硫酸软骨素中的至少一种；所述抛射剂为氮、二氧化碳或氧化亚氮的压缩气体，碳氢化合物类，氟氯烷烃类，氢氟氯烷烃类或氢氟烃类化合物。9. aerosol according to claim 1 is characterized in that, described penetrant is at least one in azone, menthol and chondroitin sulfate; Described propellant is the compression of nitrogen, carbon dioxide or nitrous oxide Gases, hydrocarbons, chlorofluoroalkanes, hydrofluorochloroalkanes or hydrofluorocarbons. 10.根据权利要求1所述的气雾剂，其特征在于，将渗透剂、工业大麻花叶香精油、药用成分与溶剂混合制成溶液；将所得溶液灌入气雾罐内，封口，充填抛射剂。10. aerosol according to claim 1, is characterized in that, penetrant, industrial hemp essential oil, medicinal ingredient and solvent are mixed to make solution; The obtained solution is poured into the aerosol can, sealed, Fill with propellant.
CN201911194896.0A 2019-11-28 2019-11-28 aerosol Pending CN111000897A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201911194896.0A CN111000897A (en) 2019-11-28 2019-11-28 aerosol
PCT/CN2020/137850 WO2021232777A1 (en) 2019-11-28 2020-12-21 Aerosol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911194896.0A CN111000897A (en) 2019-11-28 2019-11-28 aerosol

Publications (1)

Publication Number Publication Date
CN111000897A true CN111000897A (en) 2020-04-14

Family

ID=70112405

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911194896.0A Pending CN111000897A (en) 2019-11-28 2019-11-28 aerosol

Country Status (2)

Country Link
CN (1) CN111000897A (en)
WO (1) WO2021232777A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210442A (en) * 2020-10-23 2021-01-12 齐齐哈尔大学 Extraction method of hemp volatile oil and cannabidiol
CN112279752A (en) * 2020-10-30 2021-01-29 云南芙雅生物科技有限公司 Carbon dioxide supercritical extraction method of cannabinoid for industrial cannabis sativa L
WO2021232777A1 (en) * 2019-11-28 2021-11-25 云南汉木森生物科技有限责任公司 Aerosol

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123475A1 (en) * 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US20170259016A1 (en) * 2015-09-16 2017-09-14 Jynyvy Covarrubias Nebulizers and associated medication
CN107325881A (en) * 2017-07-28 2017-11-07 云南汉木森生物科技有限责任公司 The extracting process and its cannabis leaf oil product of cannabis leaf oil
CN109820786A (en) * 2019-04-03 2019-05-31 栾云鹏 One kind can repair skin injury type suncream
CN110373264A (en) * 2018-04-12 2019-10-25 汉义生物科技（北京）有限公司 A composition containing industrial hemp essential oil for tobacco products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107441452A (en) * 2017-08-24 2017-12-08 山东维赫生物科技有限公司 Compound Chinese herb plant volatile oil water-borne aerosol
CN108949363A (en) * 2018-09-26 2018-12-07 常德华馥生物技术有限公司 A kind of Solventless Extraction Process of industrial hemp floral leaf essential oil
CN110343571A (en) * 2019-07-16 2019-10-18 云南绿新生物药业有限公司 A kind of preparation method and utilization of the numb essential oil of the fire containing cannabidiol
CN111000897A (en) * 2019-11-28 2020-04-14 云南汉木森生物科技有限责任公司 aerosol

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123475A1 (en) * 2015-01-31 2016-08-04 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US20170259016A1 (en) * 2015-09-16 2017-09-14 Jynyvy Covarrubias Nebulizers and associated medication
CN107325881A (en) * 2017-07-28 2017-11-07 云南汉木森生物科技有限责任公司 The extracting process and its cannabis leaf oil product of cannabis leaf oil
CN110373264A (en) * 2018-04-12 2019-10-25 汉义生物科技（北京）有限公司 A composition containing industrial hemp essential oil for tobacco products
CN109820786A (en) * 2019-04-03 2019-05-31 栾云鹏 One kind can repair skin injury type suncream

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ETHAN B RUSSO: "Taming THC：potential cannabis synergy and phytocannabinoid-terpenoid entourage effects", 《BRITISH JOURNAL OF PHARMACOLOGY》 *
SAIMA NAZ等: "A Comparative Study on Hemp（Cannabis sativa）Essential Oil Extraction Using Traditional and Advanced Techniques", 《光谱学与光谱分析》 *
希雨: "GW的大麻气雾剂即将上市", 《国外医药·植物药分册》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232777A1 (en) * 2019-11-28 2021-11-25 云南汉木森生物科技有限责任公司 Aerosol
CN112210442A (en) * 2020-10-23 2021-01-12 齐齐哈尔大学 Extraction method of hemp volatile oil and cannabidiol
CN112279752A (en) * 2020-10-30 2021-01-29 云南芙雅生物科技有限公司 Carbon dioxide supercritical extraction method of cannabinoid for industrial cannabis sativa L
CN112279752B (en) * 2020-10-30 2022-11-11 云南芙雅生物科技有限公司 Supercritical carbon dioxide extraction method of cannabinoids for industrial cannabis sativa

Also Published As

Publication number Publication date
WO2021232777A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
Carbone et al. An updated review of the genus Humulus: a valuable source of bioactive compounds for health and disease prevention
Boukhatem et al. Lemon grass (Cymbopogon citratus) essential oil as a potent anti-inflammatory and antifungal drugs
US10172897B2 (en) Enhanced smokable therapeutic cannabis product and method for making same
US20030017216A1 (en) Isolation of herbal and cannabinoid medicinal extracts
KR20170080608A (en) Cannabis extracts and methods of preparing and using same
US11338222B2 (en) Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
CN111000897A (en) aerosol
US20190275268A1 (en) Multi-use cartridge for ingestion of cannabis-based products
CN101544927B (en) Patchouli compound extract and application thereof in cigarette
Romano et al. An overview of galenic preparation methods for medicinal cannabis
CN101249110A (en) Extraction and separation method and application of volatile oil components of plant medicinal materials
CN105132182B (en) A method for preparing galangal volatile oil based on subcritical extraction and the prepared product thereof
EP3946291A1 (en) Cannabis inhalation products and methods of production thereof
CN106433983A (en) Refining method of thyme essential oil
CN105695096A (en) Lysimachia capillipes extract and preparation method thereof
CN103735466B (en) A kind of galangal hydrolat healthcare collutory and preparation method thereof
US11602701B2 (en) Method for extraction and isolation of cannabis terpene and aromatic isolates from cannabis sativa and cannabis indica
Sharma et al. A study on antidermatophytic potential of Ocimum tenuiflorum essential oil and chemical composition evaluation
CN104568785B (en) A kind of method for determining plant source extractive of volatile oil gaseous phase free radical scavenging capacity
CN113750163A (en) Artemisia annua essential oil and white tea essential oil for treating acne and composition thereof
CN112516012A (en) Soothing agilawood compound perfume and preparation method thereof
Aumeeruddy-Elalfi et al. Extraction techniques and pharmacological potential of essential oils from medicinal and aromatic plants of Mauritius
CN104450196B (en) A kind of plant source extractive of volatile oil with gaseous phase free radical scavenging capacity and preparation method thereof
KR100427584B1 (en) Fungicide composition containing extracts derived from plant
CN104161146B (en) There is the preparation method of the daphne lilac bagged tea of easypro pharynx function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200414

RJ01 Rejection of invention patent application after publication